ÄÉÃ׿¹Ìå

ÄÉÃ׿¹Ì壨Nanobody, Nb£©£¬ÓÖ³ÆÎªµ¥Óò¿¹Ì壨Single-domain antibodies, sdAbs£©£¬ÊÇÀ´Ô´ÓÚÂæÍտƶ¯ÎïºÍöèÓãµÄÒ»ÖÖ¶ÀÌØµÄ¿¹Ì壬×î³õÓɱÈÀûʱÃâÒßѧ¼ÒHamers-CastermanÓÚ1989ÄêÔÚ·ÖÀëÂæÍÕѪÇåÖеĿ¹ÌåʱżȻ·¢ÏÖ¡£

´«Í³¿¹ÌåµÄ½á¹¹ÀàËÆÓÚ¡°Y¡±ÐΣ¬ÊÇÓÉÁ½ÌõÖØÁ´ºÍÁ½ÌõÇáÁ´¹¹³ÉµÄ¶Ô³Æ½á¹¹¡£Ò»Ð©ÂæÍտƶ¯ÎïµÈÔÚÆäÉú³¤½ø»¯µÄ¹ý³ÌÖУ¬×ÔÉíµÄÃâÒßϵͳÖгöÏÖÁËȱʧÇáÁ´¼°ÖØÁ´CH1½á¹¹µ«ÍêÈ«±£Áô¿¹Ô­½áºÏ»îÐÔµÄÖØÁ´¿¹Ì壨HCAb£©¡£HCAbÌØÒìÐÔ½áºÏ¿¹Ô­µÄÇøÓòΪÆäÖØÁ´µÄ¿É±äÇø£¬¼´VHH£¨Variable domain of heavy chain of heavy-chain antibody£©¡£VHH¾­ÖØ×é±í´ïºó£¬¿É»ñµÃÖ»º¬Óе¥¸ö½á¹¹ÓòµÄ×îСµ¥Ôª¿¹Ô­½áºÏƬ¶Î£¬¼´ÄÉÃ׿¹Ìå¡£

ÄÉÃ׿¹Ìå½öÓÐ12~14 kDa£¬Æä¾§ÌåÖ±¾¶Îª2.5 nm£¬³¤4 nm£¬Òò´Ë±»ÈÏΪÊÇÒÑÖªµÄ¿ÉÒÔÓ뿹ԭ½áºÏµÄ×îСµ¥Î»¡£

¸÷À࿹Ìå½á¹¹Ê¾Òâͼ

ͼ1 ¸÷À࿹Ìå½á¹¹Ê¾Òâͼ

ÄÉÃ׿¹ÌåµÄÓÅÊÆÌØÐÔ

ÄÉÃ׿¹Ìå»ùÓÚÖØÁ´¿¹ÌåVHHµÄÌØÊâ½á¹¹£¬¼¯´«Í³¿¹ÌåÓëС·Ö×ÓÒ©ÎïµÄÓŵãÓÚÒ»Ì壬²¢ÔÚÖî¶à·½Ãæ¿Ë·þÁË´«Í³¿¹ÌåµÄȱÏÝ£¬Öð½¥ÔÚÉúÎïÒ½Ò©Ñз¢ÓëÁÙ´²ÌåÍâÕï¶ÏÐÐÒµÖдó·Å¹â²Ê¡£ÆäÓÅÊÆÔÚÓÚ£º

1¡¢·Ö×ÓÁ¿Ð¡¡£´«Í³¿¹Ìå·Ö×ÓÁ¿Ô¼150 kDa£¬ÄÉÃ׿¹ÌåÔ¼ÊÇÆäÊ®·ÖÖ®Ò»£»²»½öÈç´Ë£¬ÄÉÃ׿¹Ìå¾ßÓм«Ç¿µÄ×éÖ¯ÉøÍ¸Á¦£¬¿ÉÖ±½Ó´©Í¸ÑªÄÔÆÁÕÏ£¬ÀûÓÚ¶ÔÖ×ÁöµÄÕï¶ÏÓë°ÐÏòÖÎÁÆ¡£

2¡¢ÃâÒßÔ­ÐԵ͡£ÄÉÃ׿¹Ìå²»º¬Fc¶Î£¬±ÜÃâÁËFc¶ÎÒýÆðµÄÃâÒß·´Ó¦£¬ÇÒÓëhuman VHµÄͬԴÐԽϸߣ¨67%~87%£©£¬ÓëÈ˵ÄÉúÎïÏàÈÝÐԽϺá£

3¡¢ÌØÒìÐÔÇ¿£¬¿¹Ô­Ç׺ÍÁ¦¸ß¡£ÓÉÓÚÖØÁ´¿É±äÇøÊÇ¿¹Ô­Ö÷Òª½áºÏÇøÓò£¬²¢ÇÒVHHµÄCDR3Çø¸ü³¤£¬°±»ùËá²Ð»ùÊýÊÇ´«Í³VHµÄ2~3±¶£¬ÕâÑùµÄ½á¹¹ÌØÐÔ£¬¿ÉÒÔÐγÉָ״͹»·²¢Ç¶È뿹ԭ·Ö×Ó¹µ²Û»òÁÑ϶ÄÚ£¬½øÒ»²½Ê¶±ð¿¹Ô­±íÃæµÄ¿×¶´»òÒþ²ØµÄ±íλ£»²»½öÈç´Ë£¬VHHµÄCDR3¿ÉÒÔºÍCDR1ÉõÖÁFR2¼ä¶àÐγÉÒ»Ìõ¶þÁò¼üÓÃÓÚÎȶ¨½á¹¹£¬¿ÉÒÔ×î´ó³Ì¶ÈÓÅ»¯½áºÏλµãµÄÍØÆË½á¹¹£¬²¢ÇÒ´Ù½øCDR3³¯Ïò¿¹Ô­µÄ·½Ïò¡£Òò´Ë£¬ÌìÈ»ÖØÁ´¿¹Ìå¼°Æä½øÒ»²½ÖØ×éµÃµ½µÄÄÉÃ׿¹Ìå¾ßÓиüÇ¿µÄ¿¹Ô­½áºÏÄÜÁ¦¡£

4¡¢ÊÊÓÃÓÚÔ­ºË±í´ïºÍ¸÷ÖÖÕæºË±í´ïϵͳ£¬´ó¹æÄ£Éú²ú³É±¾µÍ¡¢ÖÜÆÚ¶Ì¡£ÄÉÃ׿¹Ìå¾ßÓÐÇ×Ë®ÐԺ͵¥¶àëÄÐÔ£¬ÇÒȱ·¦ÌÇ»ù»¯ÐÞÊΣ¬¿ÉÔÚÔ­ºË±í´ïϵͳÖнøÐÐÖØ×éÉú²ú£¬¾ßÓÐÏ൱µÄ³É±¾Ð§Ò档ͬʱ£¬ÄÉÃ׿¹Ìå²»Ò×ɥʧÉúÎï»îÐÔ£¬Ò×ÓÚ´¢´æ¡£

5¡¢¸ßÇ×Ë®ÐÔ¡£ÆÕͨµ¥Óò¿¹ÌåÇáÖØÁ´¶Ï¿ªºó£¬VH±íÃæµÄ°±»ùËáÊèË®²Ð»ùÒò´óÁ¿±©Â¶»áÏ໥ճ¸½ÉõÖÁ¾Û¼¯³É¿é¡£¶øÔÚÄÉÃ׿¹ÌåÖУ¬FR2ÉϵÄÊèË®ÐÔ°±»ùËáVal37¡¢Gly44¡¢Leu45¡¢Trp47Í»±äΪÇ×Ë®ÐÔµÄPhe/Tyr37¡¢Glu/Gln44¡¢Arg/Cys45¡¢Gly/Phe/Ser/Leu47£¬Ë®ÈÜÐÔÔö¼Ó£¬¿¹Ìå¾ÛºÏÒò´Ë¼õÉÙ¡£

6¡¢¸ßÎȶ¨ÐÔ¡¢¸ßÄÍÐÔ¡£ÄÉÃ׿¹ÌåµÄ¸ßÎȶ¨ÐÔÀ´Ô´ÓÚÆäÄÚ²¿µÄ¶à¸ö¶þÁò¼ü£¬¿ÉÄÍÊܸßΡ¢Ç¿Ëᡢǿ¼îµÈÖ±äÐÔÌõ¼þ£¬ÔÚ90¡æ´¦ÀíºóÈÔÄܸ´ÐÔ²¢ÖØÐ»ñµÃÉúÎï»îÐÔ¡£

ÄÉÃ׿¹ÌåµÄ¾ÖÏÞ

ÄÉÃ׿¹ÌåËäÓоßÓн϶àÓÅÊÆµ«ÈÔÈ»´æÔÚ×ÅÒ»¶¨µÄ¾ÖÏÞÐÔ¡£´«Í³¿¹ÌåÖ÷Òª´Ó¿ÉÈ˹¤ËÇÑøµÄʵÑéСÊóÖлñµÃ¡£Ïà±È֮ϣ¬ÄÉÃ׿¹ÌåµÄ¿ª·¢Ô­ÁÏÔò¶àÒÀÀµ´ÓÑòÍÕµÈÂæÍտƶ¯ÎïÖнøÐÐÌáÈ¡¡£Òò´Ë£¬´ó¹æÄ£¿ª·¢ÄÉÃ׿¹ÌåÐèÒª´ó¹æÄ£µÄÐóÄÁÒµ»òÕß¶¯ÎïËÇÑø»ú¹¹¸øÓèÖ§³Ö£¬ÇÒÐèÑ¡Ôñ½¡¿µÁ¼ºÃ¡¢ÌåÐÍÊÊÖе͝ÎÕâÊÇÏà¶ÔÀ§ÄѵÄ¡£

´ËÍ⣬ÄÉÃ׿¹Ìå×÷ΪÖÎÁÆÐÔÒ©Îïʱ£¬ÓÉÓÚÆäÌå»ýС£¬Òò´ËÉöÔàÇå³ý¿ì£¬°ëË¥ÆÚ¶Ì£¬ÓÐʱÐèҪͨ¹ýһЩ·½·¨À´ÑÓ³¤Æä°ëË¥ÆÚ¡£

ΪʲôѡÓÃÑòÍÕÖÆ±¸ÄÉÃ׿¹Ì壿

  • 1¡¢ÖØÁ´¿¹ÌåÔÚÑòÍÕµÄѪÇ忹ÌåÖÐÔ¼Õ¼±È40~50%£¬ÓÐÀûÓÚÄ¿±ê¿¹ÌåµÄɸѡÓëÌáÈ¡£»
  • 2¡¢ÑòÍÕVHH³ýÁËÕý³£µÄ23λÓë104λÐγɶþÁò¼üÍ⣬ÄÉÃ׿¹Ìå¿âÖÐÔ¼30%µÄÐòÁÐÔÚ55λÓëCDR3Ö®¼ä´æÔÚ¶îÍâµÄÒ»¶Ô¶þÁò¼ü£¬¿ÉÒÔÌá¸ß¿¹Ìå½á¹¹µÄÎȶ¨ÐÔ£»
  • 3¡¢ÑòÍÕVHHÓëhuman VHµÄͬԴÐԽϸߣ¬Ô¼ÔÚ80%~87.3%Ö®¼ä£»
  • 4¡¢ÑòÍÕÖÐÖ÷Òª´æÔÚVHH3ÑÇϵ£¬VHH3µÄCDR3³¤¶È½Ï³¤£¬²¢´æÔÚ16~24¸ö°±»ùËá²Ð»ù£¬¿ÉÐγÉָ״͹»·Ç¶È뿹ԭ·Ö×Ó¹µ²Û»òÕßÁÑ϶ÖУ¬Ôö¼ÓÓ뿹ԭÏ໥×÷ÓõÄÃæ»ý£¬¾ßÓи߶ȵĿÉÈÜÐÔÓ뿹ԭ½áºÏÄÜÁ¦£»
  • 5¡¢ÑòÍÕÌå»ýС¡¢ÐÔ¸ñÎÂ˳¡¢Ò×ËÇÑø£¬±»ÈÏΪÊÇÄÉÃ׿¹ÌåµÄ×î¼ÑÀ´Ô´Ö®Ò»¡£

ÑòÍÕÌåÄÚ»¹ÓÐÆäËûÑÇÐ͵Ŀ¹ÌåÂð£¿

ÑòÍÕÌåÄÚѪÇ忹ÌåÖ÷Òª°üÀ¨IgG1£¬IgG2ºÍIgG3ÈýÖÖÑÇÐÍ£¬ÆäÖÐIgG1Ó봫ͳ¿¹Ìå½á¹¹ÏàËÆ£¬º¬ÓÐ2ÌõÖØÁ´ºÍ2ÌõÇáÁ´£»IgG2ºÍIgG3ÊÇȱÉÙCH1ºÍÇáÁ´½á¹¹ÓòµÄÖØÁ´¿¹Ìå¡£

Õ¹Íûǰ¾°

×ÔÉÏÊÀ¼Í¾ÅÊ®Äê´ú±»±¨µÀÖÁ½ñ£¬ÄÉÃ׿¹Ìå»ùÓÚÆäÓÅÔ½µÄÌØÐÔÈç·Ö×ÓÁ¿Ð¡¡¢½á¹¹Îȶ¨¡¢¿ÉÈÜÐԺá¢ÌØÒìÐÔÇ¿¡¢ÃâÒßÔ­ÐÔÈõ¡¢Éú²ú³É±¾µÍµÈ£¬ÒѾ­³ÉΪÁË¿¹Ì幤³ÌÑо¿×îÇ°ÑØµÄ¼¼ÊõÖ®Ò»£¬±»¹ã·ºÓ¦ÓÃÓÚÉúÎïѧºÍҽѧµÈÁìÓò£¬¾ßÓйãÀ«µÄÓ¦ÓÃǰ¾°¡£

²Î¿¼ÎÄÏ×
[1]Jov?evska Ivana,Muyldermans Serge. The Therapeutic Potential of Nanobodies.[J]. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy,2020,34(1).
[2]ÑÏê»,·ë½¨Ô¶,ÕÅ×ÓÒÇ,ÑîËÉöÎ,Ðì´ºÓê,ΤÃÈ,»ÆÇ导,³Âº£À¼.ÄÉÃ׿¹ÌåµÄÖÆ±¸ÓëÁÙ´²Ó¦ÓÃÑо¿½øÕ¹[J].ÖйúÐóÄÁÊÞÒ½, 2021,48(02)£º685-694.DOI: 10.16431/j.cnki.1671-7236.2021.02.031.

Ïà¹Ø·þÎñ

Ïà¹ØÔĶÁ

Á¢¼´Ñ¯¼Û
  • ÐÕÃû

  • µ¥Î»

  • µç»°

  • ×ÉѯÏîÄ¿

  • ÑéÖ¤Âë

  • ÁôÑÔ:

¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿